![John Tsai](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
John Tsai
Directeur Technique/Scientifique/R&D chez
DAIICHI SANKYO COMPANY, LIMITED
Profil
John Tsai is Chief Executive Officer at Forcefield Therapeutics Ltd. since 2023.
Dr. Tsai is Chairman & Managing Director at SwanBio Therapeutics, Inc. since 2023.
Dr. Tsai is Chairman at Purespring Therapeutics Ltd. Dr. Tsai is Director at Spur Therapeutics Ltd. Dr. Tsai is Global Head-Research & Development at Daiichi Sankyo Co., Ltd. starting 2026.
Dr. Tsai is Executive Partner at Syncona Ltd. since 2023.
Former roles include Independent Director at Blueprint Medicines Corp.
from 2023 to 2025, Chief Medical Officer & SVP-Global Medical at Amgen, Inc. from 2017 to 2018, Head-Clinical Development at Bristol Myers Squibb Co. from 2016 to 2017, Chief Medical Officer & President at Novartis AG from 2018 to 2022, Executive Partner at Syncona Partners LLP from 2023 to 2026, and Director at Novartis Institute for Functional Genomics, Inc. Education includes undergraduate studies at Washington University in St. Louis and a doctorate from the University of Louisville School of Medicine.
Postes actifs de John Tsai
| Sociétés | Poste | Début |
|---|---|---|
| SYNCONA LIMITED | Corporate Officer/Principal | 01/01/2023 |
| DAIICHI SANKYO COMPANY, LIMITED | Directeur Technique/Scientifique/R&D | 01/04/2026 |
Forcefield Therapeutics Ltd.
 Forcefield Therapeutics Ltd. BiotechnologyHealth Technology Develops therapeutics to retain heart function via protection of cardiomyocytes | Directeur Général | 27/09/2023 |
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage gene therapy company that develops treatments for neurological disorders | Président | 16/10/2023 |
Purespring Therapeutics Ltd.
 Purespring Therapeutics Ltd. BiotechnologyHealth Technology Develops therapeutics for the treatment of kidney diseases | Président | - |
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company, which developing gene therapies for bleeding and other debilitating disorders | Directeur/Membre du Conseil | - |
Anciens postes connus de John Tsai
| Sociétés | Poste | Fin |
|---|---|---|
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners invests in companies located across the globe. The firm focuses on life science businesses and therapeutic areas.. It participates in early stage capital requirements. | Private Equity Investor | 01/02/2026 |
| BLUEPRINT MEDICINES CORPORATION | Directeur/Membre du Conseil | 17/07/2025 |
| NOVARTIS AG | Directeur Technique/Scientifique/R&D | 15/05/2022 |
| ░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
Formation de John Tsai
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
65
Relations au 1er degré
14
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 14 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Washington University in St. Louis
 Washington University in St. Louis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Syncona Ltd.
 Syncona Ltd. Investment Trusts/Mutual FundsMiscellaneous Acts as Closed-End Investment Fund/Investment Trust | Miscellaneous |
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Daiichi Sankyo Co., Ltd.
 Daiichi Sankyo Co., Ltd. Pharmaceuticals: MajorHealth Technology Engages in the manufacture and sale of pharmaceutical products | Health Technology |
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts research related to biotechnology and medicine | Commercial Services |
Blueprint Medicines Corp.
 Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners invests in companies located across the globe. The firm focuses on life science businesses and therapeutic areas.. It participates in early stage capital requirements. | Finance |
University of Louisville School of Medicine
 University of Louisville School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company, which developing gene therapies for bleeding and other debilitating disorders | Health Technology |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage gene therapy company that develops treatments for neurological disorders | Health Technology |
Purespring Therapeutics Ltd.
Purespring Therapeutics Ltd. BiotechnologyHealth Technology Develops therapeutics for the treatment of kidney diseases | Health Technology |
Forcefield Therapeutics Ltd.
Forcefield Therapeutics Ltd. BiotechnologyHealth Technology Develops therapeutics to retain heart function via protection of cardiomyocytes | Health Technology |
